Evaluation of a novel real-time PCR test based on the ssrAgene for the identification of group B streptococci in vaginal swabs by Martina Wernecke et al.
BioMed CentralBMC Infectious Diseases
ssOpen AcceTechnical advance
Evaluation of a novel real-time PCR test based on the ssrA gene for 
the identification of group B streptococci in vaginal swabs
Martina Wernecke1, Ciara Mullen1, Vimla Sharma3, John Morrison3, 
Thomas Barry1,2, Majella Maher*1 and Terry Smith1
Address: 1Molecular Diagnostics Research Group, National Centre for Biomedical Engineering Science, Galway, Ireland, 2Microbiology, School of 
Natural Sciences, National University of Ireland, Galway, Ireland and 3Department of Obstetrics and Gynaecology, University College Hospital 
Galway, Ireland
Email: Martina Wernecke - martina.wernecke@nuigalway.ie; Ciara Mullen - ciara.mullen@nuigalway.ie; 
Vimla Sharma - vimla.sharma@nuigalway.ie; John Morrison - john.morrison@nuigalway.ie; Thomas Barry - thomas.barry@nuigalway.ie; 
Majella Maher* - majella.maher@nuigalway.ie; Terry Smith - terry.smith@nuigalway.ie
* Corresponding author    
Abstract
Background: Despite the implementation of prevention guidelines, early-onset group B
streptococci (GBS) disease remains a cause of neonatal morbidity and mortality worldwide.
Strategies to identify women who are at risk of transmitting GBS to their infant and the
administration of intrapartum antibiotics have greatly reduced the incidence of neonatal GBS
disease. However, there is a requirement for a rapid diagnostic test for GBS that can be carried
out in a labour ward setting especially for women whose GBS colonisation status is unknown at
the time of delivery. We report the design and evaluation of a real-time PCR test (RiboSEQ GBS
test) for the identification of GBS in vaginal swabs from pregnant women.
Methods: The qualitative real-time PCR RiboSEQ GBS test was designed based on the bacterial
ssrA gene and incorporates a competitive internal standard control. The analytical sensitivity of the
test was established using crude lysate extracted from serial dilutions of overnight GBS culture
using the IDI Lysis kit. Specificity studies were performed using DNA prepared from a panel of GBS
strains, related streptococci and other species found in the genital tract environment. The RiboSEQ
GBS test was evaluated on 159 vaginal swabs from pregnant women and compared with the
GeneOhm™ StrepB Assay and culture for the identification of GBS.
Results: The RiboSEQ GBS test is specific and has an analytical sensitivity of 1-10 cell equivalents.
The RiboSEQ GBS test was 96.4% sensitive and 95.8% specific compared to "gold standard" culture
for the identification of GBS in vaginal swabs from pregnant women. In this study, the RiboSEQ GBS
test performed slightly better than the commercial BD GeneOhm™ StrepB Assay which gave a
sensitivity of 94.6% and a specificity of 89.6% compared to culture.
Conclusion: The RiboSEQ GBS test is a valuable method for the rapid, sensitive and specific
detection of GBS in pregnant women. This study also validates the ssrA gene as a suitable and
versatile target for nucleic acid-based diagnostic tests for bacterial pathogens.
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Group B Streptococcus (GBS) (Streptococcus agalactiae) is
one of the leading causes of neonatal morbidity and mor-
tality in the developed world. Early-onset GBS disease
occurs within the first week of life and is associated with
neonatal sepsis, pneumonia and meningitis. The mortal-
ity rate averages at 6.5% for early-onset GBS cases and for
infected preterm infants it rises to 22.7% [1].
Approximately 10 - 40% of pregnant women carry GBS
asymptomatically in their vagina or rectum [2-4]. Trans-
mission to the infant occurs vertically during labour via
fetal aspiration of infected amniotic fluid or during pas-
sage through the birth canal. Since the implementation of
intrapartum antibiotic prophylaxis (IAP) for the preven-
tion of GBS, the incidence of early-onset GBS disease in
neonates has decreased significantly although resistance
to certain antimicrobials has been reported [5]. Studies in
the US show that incidence has declined from 1.5/1000
live births in 1990 [6] to 0.32/1000 live births in 2003 [1].
In the UK, early-onset GBS disease is reported to occur in
0.5/1000 births [7].
Practices recommended by public health authorities for
the identification of at-risk women who should receive
antibiotic treatment during labour vary internationally.
Centres for Disease Control and Prevention (CDC) guide-
lines for the prevention of perinatal GBS disease recom-
mend a universal, microbiological culture-based prenatal
screening strategy at 35 - 37 weeks' gestation combined
with IAP for GBS-colonised women [2]. Conversely, the
risk factor approach relies on the presence of one or more
of the following intrapartum factors as indicators for
increased risk of neonatal GBS infection: previous infant
with early-onset GBS disease, premature labour, pro-
longed rupture of membranes and fever [7]. A comparison
of the two strategies showed that the culture-based
approach was almost 50% more effective in preventing
early-onset GBS disease [8]. The UK-based Royal College
of Obstetricians and Gynaecologists (RCOG) opposes the
practice of universal screening and widespread use of
intrapartum antibiotics due to a lack of clear evidence of
the effectiveness of such practices in controlling the inci-
dence of neonatal sepsis [7]. A recent UK study which
looked at the cost-effectiveness of prenatal screening and
treatment strategies for the prevention of GBS and other
bacterial infections in early infancy proposed that treat-
ment of all pre-term and high-risk term groups would be
beneficial [9].
Perinatal GBS disease prevention practices have been suc-
cessful in lowering neonatal GBS disease by 50 - 80%
[10,11]. Nevertheless, early-onset GBS disease cases con-
tinue to occur, leading to acute clinical complications
especially for preterm infants [12]. There is a requirement
for a rapid diagnostic test for GBS that can be performed
in a labour ward setting to ascertain the GBS colonisation
status of women in labour, those in preterm labour or
women who have not had prenatal care. For these
women, culture-screening is not useful because of the
time it takes to obtain test results. Several reports demon-
strate that real-time PCR is a rapid, more sensitive method
than standard culture for determining the intrapartum
GBS colonisation status [13-17]. As a result, intrapartum
antibiotic prophylaxis can be administered more effec-
tively, thereby reducing the transmission rates of GBS to
infants and consequently lowering infant morbidity and
mortality rates.
The objective of this study was to develop a rapid nucleic
acid diagnostic test for GBS that can be performed in a
wide variety of labour and delivery settings. The real-time
PCR test developed in this study targets the bacterial ssrA
gene which was previously shown to be a versatile diag-
nostic target for important food and clinical pathogens
[18,19]. The performance of the RiboSEQ GBS test was
compared to the commercial FDA-cleared BD GeneOhm™
StrepB Assay (Becton, Dickinson and Company, New Jer-
sey, USA). The results from these tests were correlated




Vaginal swabs from pregnant women (n = 39) were
sourced from the Dept. of Obstetrics and Gynaecology,
University College Hospital Galway (UCHG), Ireland.
Ethics consent was obtained for the study from the
Research Ethics Committee at UCHG for vaginal swabs
only. Duplicate vaginal swabs were collected into Amies
transport medium (Sarstedt, Nümbrecht, Germany),
transported to the laboratory at ambient temperature
within 3 to 4 hours of collection and processed immedi-
ately.
Vaginal swab specimens from pregnant women (n = 120)
were purchased from The New England Life Science
Group (NELSG) (Los Osos, CA, USA), a clinical services
organization. These specimens were remnant swabs
screened for GBS colonisation by USA hospital laborato-
ries as part of routine prenatal care. GBS was identified in
these swabs at source by genital screen cultures or by selec-
tive GBS culture. The remnant specimens were frozen
within 1 - 3 days of sampling and shipped on dry ice to
our laboratory. A proportion of 90% GBS-positive speci-
mens (n = 107) was requested from NELSG. Those under-
taking the performance evaluation of the nucleic acid tests
were blinded to the results of the US microbiological anal-
ysis while the study was in progress.Page 2 of 8
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One of the duplicate antenatal specimens collected from
UCHG was used for microbiological evaluation. The swab
was inoculated into 7 ml LIM broth (Todd-Hewitt broth
with 15 μg/ml nalidixic acid and 10 μg/ml colistin) (LIP
Diagnostic Services, Galway, Ireland), incubated over-
night and subcultured onto TSA + 5% sheep blood agar
(LIP) for 18 - 24 h at 37°C according to CDC recommen-
dations for GBS culture processing. Presumptive GBS col-
onies showing β-haemolysis were confirmed using the
catalase test and antigen detection (Streptococcal Group-
ing kit, Oxoid, Cambridge, UK). Plates showing no colony
growth were reincubated for a further 24 hours and rein-
spected. Remnant specimens collected from US sites were
screened at source for GBS using the CDC-recommended
method described above or by genital culture including
LIM broth culture.
Sample preparation
The commercially available crude lysis kit BD GeneOhm™
Lysis Kit (BD, NJ, USA) was used for sample preparation.
The second swab of duplicate UCHG specimens and rem-
nant swabs were vortexed for 2 min in 1 ml of sample
buffer. Four hundred microlitres of the suspension was
transferred into the lysis tube and lysed by mechanical dis-
ruption with silica beads according to manufacturer's
instructions. Lysates were stored at -20°C until required.
Construction of IAC
An internal amplification control (IAC) was constructed
using the composite primer approach described by Hoor-
far et al. [20,21] and O'Grady et al. [19]. An internal
amplification control consisting of heterologous DNA
cloned into a plasmid vector was included in the RiboSEQ
GBS test to identify false negative test results caused by
PCR inhibition. The IAC is co-amplified with the GBS tar-
get and detected by an IAC-specific hybridization probe
(Table 1) included in the real-time PCR reaction.
RiboSEQ GBS real-time PCR test
The ssrA genes of 10 GBS strains which represent 7 sero-
types including the 5 most commonly occurring serotypes
(Ia, Ib, II, III, V) were sequenced (Sequiserve, Vaterstetten,
Germany) and aligned with other related streptococci
(Table 2) ssrA sequences generated in this study or availa-
ble on the tmRNA website [22]. From these alignments,
oligonucleotide primers gbsU3F and gbsU4R were
designed to amplify a 293 bp PCR product from the GBS
ssrA gene. A fluorescently labelled hybridization probe
pair (f1GBS-Flu and f2GBS-LC640) was designed for the
detection of GBS. BLAST (Basic Local Alignment Search
Tool) analysis of the hybridization probe sequences was
performed to confirm in silico specificity of the probes for
the detection of GBS.
Real-time PCR was performed in a 20 μl reaction volume
on the LightCycler® instrument using the "LightCycler®
FastStart DNA Master HybProbe" kit (Roche Diagnostics,
Mannheim, Germany). Each reaction contained reagents
to final concentrations of: 5 mM MgCl2, 0.5 μM each
primer (Table 1), 0.2 μM each hybridization probe (Table
1), 0.5 U uracil-DNA glycosylase (Roche). Template was
added in 2 μl volumes and IAC was added as 100 recom-
binant plasmid copies per reaction. Thermal cycling
parameters consisted of 95°C denaturation for 10 min
followed by 50 amplification cycles of 95°C for 10 s,
50°C for 15 s and 72°C for 10 s. Melting profiles were run
between 40°C and 80°C at a transition rate of 0.1°C/s.
Analytical sensitivity of the RiboSEQ GBS real-time PCR 
test
The limit of detection (LOD) was established using crude
lysate extracted from serial dilutions of overnight GBS cul-
ture (BCCM 15081) using the IDI Lysis kit (GeneOhm
Sciences, Canada). Colony forming units (cfu) per dilu-
tion were established by triplicate plate counts and real-
time PCR reactions included GBS crude lysate template
containing between 105 and 10-1 cell equivalents.
Table 1: Oligonucleotide primers and hybridization probes used in this study
Name Function Sequence 5' - 3'
gbsU3F Forward primer GACAGGCATTATGAGGTA
gbsU4R Reverse primer GCTAATATATTTGTCTACAAC
CompF Forward composite primer for IAC generation GACAGGCATTATGAGGTAATACCCAACTTGGAATG
CompR Reverse composite primer for IAC generation GCTAATATATTTGTCTACAACTCTTCACCAGAATAAAATTG
tmUF Universal bacterial ssrA forward primer GGGG(A/C)(C/T)TACGG(A/T)TTCGAC
tmUR Universal bacterial ssrA reverse primer GGGA(A/G)TCGAACC(A/G)(C/G)GTCC
f1GBS-Flu GBS-specific hybridization probe TTGCGTTTTGCTAGAAGGTCTTA - Flu
f2GBS-LC640 GBS-specific hybridization probe LC640- TATCAGCAAACTACGTTTGGCT - Ph
ALS1-Flu IAC-specific hybridization probe TGAATGTATCCCCTGGA - Flu
ALS1-LC705 IAC-specific hybridization probe LC705 - TGGCACTGGTACCATCTAA - PhPage 3 of 8
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The performance of the RiboSEQ GBS real-time PCR test
for the detection of GBS in clinical samples was bench-
marked against the performance of the commercially
available FDA-approved BD GeneOhm™ StrepB Assay
which targets the CAMP factor B (cfb) gene. The assay was
performed on the SmartCycler® instrument (Cepheid, Cal-
ifornia, USA) according to manufacturer's instructions.
Briefly, 25 μl of diluent was added to each Master Mix
reaction tube. Positive and negative control tubes were
included in each run. Sample crude lysates were added to
the Master Mix tubes in 1.5 μl volumes, the tubes were
briefly centrifuged and placed in the SmartCycler® instru-
ment. Assay runs were performed using the BD Gene-
Ohm™ StrepB Assay-specific software. The BD
GeneOhm™ StrepB Assay takes approximately 60 min to
run including sample preparation.
Results
Analytical sensitivity and specificity of the RiboSEQ GBS 
real-time PCR test
The limit of detection of the RiboSEQ GBS test was deter-
mined by three independent experimental assessments
and consistently detected in the range of 1 - 10 cell equiv-
alents per reaction. The inclusion of an internal amplifica-
tion control at a concentration of 100 plasmid copies per
test did not lower the LOD (data not shown). At high GBS
template concentrations (≥ 105 cell equivalents/reaction)
the amplification of internal control target was occasion-
ally inhibited due to competition between GBS target
DNA and IAC in the PCR reaction.
Specificity studies were performed using DNA prepared
from a panel of 10 GBS strains representing 7 serotypes
including 5 common serotypes and 42 related strepto-
cocci and other species found in the genital tract environ-
ment (Table 2). All 10 GBS strains were detected. The test
was negative for all non-GBS species listed in Table 2. The
DNA extracted from non-GBS species was confirmed to be
Table 2: Bacterial species and strains used to test the specificity of the RiboSEQ real-time PCR test
GBS Serotype Collection ref no Stool Panel Collection ref no
Streptococcus agalactiae Ia BCCM 15081 Escherichia coli DSM 30038
Streptococcus agalactiae Ib BCCM 15082 Morganella morganii DSM 30164
Streptococcus agalactiae Ic BCCM 15083 Proteus mirabilis DSM 4479
Streptococcus agalactiae II BCCM 15084 Klebsiella pneumoniae Clinical isolate
Streptococcus agalactiae III BCCM 15085 Escherichia hermannii DSM 4560
Streptococcus agalactiae IV BCCM 15086 Escherichia vulneris DSM 4564
Streptococcus agalactiae V BCCM 15087 Aeromonas hydrophila DSM 30015
Streptococcus agalactiae Ib BCCM 15090 Citrobacter freundii DSM 30039
Streptococcus agalactiae III BCCM 15094 Enterobacter cloacae ATCC 13047
Streptococcus agalactiae III BCCM 15095
Respiratory Panel
Strep spp Staphylococcus aureus DSM 11965
Streptococcus dysgalactiae DSM 6176 Staphylococcus epidermidis ATCC 27626
Streptococcus oralis DSM 20627 Pseudomonas aeruginosa ATCC 10145
Streptococcus pneumoniae DSM 11865 Klebsiella oxytoca DSM 5175
Streptococcus parasanguinis DSM 6778
Streptococcus intermedius DSM 20573 Neisseria Panel
Streptococcus salivarius DSM 20560 Neisseria meningitidis DSM 10036
Streptococcus uberis DSM 20569 Neisseria lactamica DSM 4691
Streptococcus mitis DSM 12643 Neisseria meningitidis ATCC 13077
Enterococcus faecalis DSM 20371 Neisseria cinerea DSM 4630
Enterococcus faecium DSM 20477
Streptococcus gordonii DSM 6777 Sepsis Panel
Streptococcus mutans DSM 20523 Streptococcus sanguis DSM 20567
Streptococcus pyogenes DSM 20565 Streptococcus porcinus DSM 20725
Streptococcus anginosus DSM 20563 Serratia marcescens DSM 1608
Enterobacter aerogenes DSM 30053
Genital Panel Staphylococcus haemolyticus DSM 20263
Acinetobacter lwoffii DSM 2403 Streptococcus bovis DSM 20480
Lactobacillus acidophilus DSM 20079
Lactobacillus fermentum DSM 20055
Mobiluncus curtisii DSM 2711
Mobiluncus mulieris DSM 2710Page 4 of 8
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and tmUR (Table 1) which were designed to amplify the
bacterial ssrA gene.
Evaluation of the RiboSEQ GBS test in clinical samples
Performance of the RiboSEQ GBS test was compared to the
results of microbiological culture methods for the isola-
tion of GBS. Test results were also compared to those
obtained using the commercial BD GeneOhm™ StrepB
Assay. Microbiological culture results were used as the
gold standard.
A total of 159 specimens (39 from UCHG, 120 from
NELSG) were tested by microbiological culture, RiboSEQ
GBS real-time PCR and BD GeneOhm™ StrepB Assay.
Microbiological culture identified 111 samples as GBS-
positive and 48 samples as GBS-negative.
The prevalence of GBS colonisation among the specimens
collected from UCHG was 10.3% (4/39) using the GBS
selective culture method. Calculation of prevalence of
GBS colonisation in the NELSG samples is not applicable
since this population of specimens was selected to be pre-
dominantly GBS-positive and not representative of the
true prevalence among pregnant women.
In 146 samples, the results of all three tests showed 100%
correlation, where 104 samples were identified as GBS-
positive and 42 samples were identified as GBS-negative.
In 95% of samples the two nucleic acid diagnostic test
(NAD) results agreed (151/159).
Discrepant results were obtained in a total of 13 samples
after retesting the crude lysate. In 5 samples, NAD test
results agreed but conflicted with the microbiology
results. Microbiological culture identified 2 samples as
GBS-negative which the NAD tests identified as GBS-pos-
itive. Three samples were determined as GBS-positive by
culture and tested negative in the NAD tests.
In one sample, the RiboSEQ GBS test was negative for a
sample that was GBS-positive by both culture and BD
GeneOhm™ StrepB Assay. PCR inhibition was not appar-
ent since the IAC gave a positive signal.
For 6 samples, the BD GeneOhm™ StrepB Assay results
disagreed with concurring culture and GBS real-time PCR
results (3 false positives, 3 false negatives).
In another sample, both the IAC and the RiboSEQ GBS test
results were negative, indicating PCR inhibition. This
specimen was identified as GBS-negative by both culture
and BD GeneOhm™ StrepB Assay with no indication of
PCR inhibition. However, the discrepancy was resolved
for this sample by increasing the IAC to 200 plasmid cop-
ies in the RiboSEQ GBS real-time PCR reaction which
yielded a positive result for the IAC for this sample.
Table 3 shows the sensitivity, specificity, predictive values
and likelihood ratios for the RiboSEQ GBS test and the BD
GeneOhm™ StrepB Assay using microbiological culture
for the identification of GBS as the gold standard. Confi-
dence intervals (CI) are stated at the 95% level.
Table 3: Sensitivity, specificity, predictive values (PPV, NPV) and likelihood ratios +LR, -LR) for the RiboSEQ GBS test and the BD 
GeneOhm™ StrepB Assay
RiboSEQ GBS test BD GeneOhm™ StrepB Assay
Positive Negative Positive Negative
Culturea Positive 107 4 105 6
Negative 2 46 5 43
Sensitivity 96.4% 94.6%
95% CI (90.5 - 98.8%) (88.1 - 97.8%)
Specificity 95.8% 89.6%
95% CI (84.6 - 99.3%) (76.6 - 96.1%)
PPVb 98.2% 95.5%
95% CI (92.9 - 99.7%) (89.2 - 98.3%)
NPVb 92% 87.8%
95% CI (79.9 - 97.4%) (74.5 - 94.9%)
+LRb 23.1 9.1
95% CI (5.9 - 89.9) (3.9 - 20.8)
-LRb 0.04 0.06
95% CI (0.01 - 0.1) (0.03 - 0.13)
Calculated using programme available at http://faculty.vassar.edu/lowry/clin1.html
a using culture as the gold standard (n = 159)
b sample population comprised of random (n = 39) and non-random (n = 120) specimensPage 5 of 8
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In a systematic review of the accuracy and rapidity of var-
ious intrapartum GBS colonisation tests, real-time PCR
was identified as one of two feasible methods for maternal
intrapartum screening [23]. Several studies have demon-
strated the speed, sensitivity and accuracy of real-time
PCR tests for the detection of GBS in pregnant women
[14,24,25]. Recently, a real-time PCR assay for the detec-
tion of ST-17 serotype III, a virulent strain of GBS associ-
ated with neonatal invasive infections was developed
[26]. Clinical studies have shown an increase in sensitivity
for real-time PCR tests in comparison to the gold standard
culture method [13,27]. Higher detection rates of real-
time PCR tests may be explained by the inability of culture
to detect low numbers of organisms, the presence of
antagonistic organisms, or possibly the detection of non-
viable cells [10].
A relatively low carriage rate obtained by culture for GBS
in this study was similar to the carriage rate of 8%
reported in a recent study where vaginal swabs from preg-
nant women were screened for GBS [28]. Ideally, both
vaginal and rectal swabs are required to ensure the highest
possible GBS detection rate [29]. However, for this study
rectal samples were not available since the specimens
were collected during routine prenatal care for the pur-
pose of general microbiological screening. Additionally,
only colonies showing β-haemolysis were tested with the
catalase and latex agglutination tests. The CDC method
also recommends testing characteristic colonies without
β-haemolysis.
In this study we developed a qualitative real-time PCR test
for the detection of GBS that is rapid (75 min including
sample preparation) and capable of detecting 1 - 10
genome copies of GBS. The sensitivity and specificity
achieved with the test in comparison to culture were
96.4% (CI 95% 90.5 - 98.8) and 95.8% (CI 95% 84.6 -
99.3), respectively. These values compare well with previ-
ously published sensitivities and specificities of real-time
PCR assays for GBS [14,15,29,24,27] (Table 4). In our
hands, the RiboSEQ GBS real-time PCR test performed
slightly better than the commercial FDA-approved BD
GeneOhm™ StrepB Assay (sensitivity 94.6% (CI 95% 88.1
- 97.8), specificity 89.6% (CI 95% 76.6 - 96.1)). Two pre-
vious studies evaluated the clinical performance of the BD
GeneOhm™ StrepB Assay and reported a sensitivity of
94% and a specificity of 95.9% for direct detection [14]
and a sensitivity of 92.5% and a specificity of 92.5% after
4 h selective enrichment [16].
Test results from the real-time PCR tests correlated in 95%
of samples. In five samples the culture results disagreed
with concurring NAD test results. Two of these 5 samples
were identified as culture-negative but GBS-positive by
both real-time PCR tests. Increased sensitivities for real-
time PCR diagnostic tests over the standard culture
method have been reported in other studies [8,13,14] and
can be a result of detection of non-viable cells, low bacte-
rial burden [13,16] or the presence of antagonistic micro-
organisms which inhibit growth in culture [30,31]. In
three cases, the PCR tests were negative for culture-posi-
tive samples. However, this discrepancy may be due to
misidentification of GBS during culture screening. Two of
these specimens were screened by genital culture and GBS
growth may have been misidentified. The third sample
was a UCHG duplicate swab in which the DNA may have
been degraded. This sample had been stored at 4°C for 5
days before processing for real-time PCR.
Due to the dynamic status of vaginal GBS colonisation,
screening intrapartum is the most accurate method of pre-
dicting the GBS colonisation status [2,32]. Screening for
GBS at the time of delivery allows antibiotics to be used
more effectively thereby rationalising their use and mini-
mising associated risks. The value of a rapid and accurate
Table 4: Comparison of sensitivities and specificities of a selection of diagnostic real-time PCR assays for GBS (using culture for GBS as 
gold standard)
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premature delivery of <35 weeks gestation when screening
results may not be available and babies are at greatest risk
of developing early-onset GBS disease.
In spite of the advantages of sensitivity, specificity and fast
turnaround time, the complexity of real-time PCR tech-
nology poses limitations to its widespread application in
clinical laboratory testing. Generally, it requires trained
personnel and dedicated laboratory areas. In addition,
specimens are often batched for analysis prolonging turn-
around time. However, these limitations have been
reduced through the development of fully integrated and
automated in vitro diagnostic platforms which are moder-
ately complex in their operation and can be performed in
an on-demand schedule [33]. These platforms provide the
potential for diagnostic tests such as the RiboSEQ GBS test
to be employed in hospital laboratories and near-patient
settings where a rapid and reliable diagnosis is most valu-
able.
Conclusion
In summary, a rapid and sensitive qualitative test for the
detection of GBS in vaginal swabs by real-time PCR was
developed. The test targets the bacterial ssrA gene which
was previously shown to be a suitable and versatile diag-
nostic target for important food and clinical pathogens.
The method has potential to be employed as a screening
and/or diagnostic test for use in clinical laboratories
where an assessment of the patient's GBS colonisation sta-
tus at the time of delivery is required without delay.
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